Pexidartinib Long‐Term Hepatic Safety Profile in Patients with Tenosynovial Giant Cell Tumors

BACKGROUND: Pexidartinib is approved in the U.S. for tenosynovial giant cell tumors (TGCTs). Herein, we assessed the hepatic safety profile of pexidartinib across patients with TGCTs receiving pexidartinib. MATERIALS, AND METHODS: Hepatic adverse reactions (ARs) were assessed by type and magnitude o...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncologist
Egile Nagusiak: Lewis, James H., Gelderblom, Hans, van de Sande, Michiel, Stacchiotti, Silvia, Healey, John H., Tap, William D., Wagner, Andrew J., Pousa, Antonio Lopez, Druta, Mihaela, Lin, Chia‐Chi, Baba, Hideo A., Choi, Youngsook, Wang, Qiang, Shuster, Dale E., Bauer, Sebastian
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley & Sons, Inc. 2020
Gaiak:
Sarcomas
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8100574/
https://ncbi.nlm.nih.gov/pubmed/33289960
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13629
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak